December 3, 2019 / 12:48 PM / 5 days ago

Ardelyx's kidney disease drug reduces elevated phosphate levels in late-stage study

Dec 3 (Reuters) - Ardelyx Inc said on Tuesday its experimental drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease in a late-stage study.

The treatment, Tenapanor, showed a greater difference in serum phosphorus levels compared to placebo, the company said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below